AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax

Leukemia Research Reports

Anne S Renteria¹  Soon Khai Low²  Suparna Nanua³  Mehul Patel⁴ 

[1] Acute Leukemia &Department of Internal Medicine, Rochester General Hospital, NY, United States;Department of Pathology, Rochester General Hospital, NY, United States;Hematology Oncology, Lipson Cancer Institute, Rochester General Hospital, NY, United States;

关键词: Acute myeloid leukemia;    Philadelphia chromosoome;    Decitabine;    Venetoclax;    Tyrosine kinase inhibitor;   

DOI  :  

来源: DOAJ

【 摘 要 】

A patient with history of myelodysplastic syndrome (MDS) presented with multifocal pneumonia and was found to have Philadelphia chromosomepositive (Ph+) acute myeloid leukemia (AML). A tyrosine kinase inhibitor (TKI) was added to decitabine and venetoclax combination, providing a molecular and cytogenetic complete response despite additional cytogenetic and molecular abnormalities. She remains in remission after eleven cycles of treatment. Our report describes the tolerability and success of a triplet regimen that incorporates a TKI to a backbone of decitabine and venetoclax in a patient with high-risk disease and with significant comorbidities.

【 授权许可】

Unknown